97 results on '"Richardson, Paul G."'
Search Results
2. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
3. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma
4. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma
5. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial
6. Impact of concomitant dexamethasone dosing schedule on bortezomib‐induced peripheral neuropathy in multiple myeloma
7. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low‐dose dexamethasone: A pooled analysis
8. Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma
9. Supplement to: Targeting CD38 with daratumumab monotherapy in multiple myeloma.
10. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
11. Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma
12. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenströmʼs macroglobulinemia
13. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
14. Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens
15. Resolving the daratumumab interference with blood compatibility testing
16. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide–bortezomib combinations
17. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study
18. Current treatment landscape for relapsed and/or refractory multiple myeloma
19. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide
20. Current strategies for treatment of relapsed/refractory multiple myeloma
21. The comprehensive clinical management of multiple myeloma and related-plasma cell disorders
22. Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells
23. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
24. Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial
25. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation
26. Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents
27. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
28. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib
29. Latest advances and current challenges in the treatment of multiple myeloma
30. Management of myeloma-associated renal dysfunction in the era of novel therapies
31. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*
32. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings
33. Monoclonal antibodies in the treatment of multiple myeloma
34. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma
35. Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study
36. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma
37. Setting the standard for newly diagnosed multiple myeloma
38. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma
39. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications
40. Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers
41. Tanespimycin as Antitumor Therapy
42. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study
43. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
44. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study
45. The evolution and impact of therapy in multiple myeloma
46. In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
47. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma
48. Thalidomide maintenance in multiple myeloma
49. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline
50. Monoclonal Antibody-Based Therapies in Human Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.